联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

休市中 07-31 16:08:41

8.920

-0.230

-2.51%

最高9.170	最低8.890	成交量639.35万
今开9.110	昨收9.150	日振幅3.06%
总市值175.72亿	流通市值175.72亿	总股本19.70亿
成交额5,724万	换手率0.32%	流通股本19.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":8.92,"timestamp":1785485321006,"preClose":9.15,"halted":0,"volume":6393500,"delay":0,"changeRate":-0.02513661202185797,"floatShares":1970000000,"shares":1970000000,"eps":1.2845604634748855,"marketStatus":"休市中","change":-0.23,"latestTime":"07-31 16:08:41","open":9.11,"high":9.17,"low":8.89,"amount":57238435,"amplitude":0.030601,"askPrice":8.92,"askSize":34000,"bidPrice":8.91,"bidSize":58000,"shortable":3,"etf":0,"ttmEps":1.3582790259969417,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":7,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":9.15,"dividendRate":0.054354,"openAndCloseTimeList":[[1785461400000,1785470400000],[1785474000000,1785484800000]],"volumeRatio":1.6073641034446031,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2652447086","title":"联邦制药再收诺和诺德1350万美元里程碑款 ，6月启动Ⅲ期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2652447086","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652447086?lang=zh_cn&edition=full","pubTime":"2026-07-17 14:13","pubTimestamp":1784268798,"startTime":"0","endTime":"0","summary":"7月16日，联邦制药发布公告，其附属公司联邦生物科技（珠海横琴）有限公司已于7月15日收取诺和诺德支付的UBT251注射液里程碑付款1350万美元（扣除丹麦预缴税后）。该笔款项对应UBT251超重或肥胖适应证的全球Ⅱ期临床里程碑。记者了解到，此次付款源于双方于去年3月订立的独家许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173810959226.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173810959226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933","IE00B3M56506.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413669","title":"联邦制药：联邦生物科技已收取诺和诺德支付的1350万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413669","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651413669?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:31","pubTimestamp":1784176297,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173738811","title":"联邦制药（03933）收到诺和诺德1350万美元UBT251全球II期里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1173738811","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173738811?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174730,"startTime":"0","endTime":"0","summary":"2026年7月16日，联邦制药国际控股有限公司公告称，其附属公司联邦生物科技已于2026年7月15日根据与诺和诺德于2025年3月24日签署的UBT251独家许可协议，收到全球超重或肥胖适应症II期临床试验的里程碑付款1,350万美元。根据该独家许可协议，联邦生物科技有资格在满足若干开发及销售目标后，累计获得最高18亿美元的潜在里程碑付款，并可按相关地区年度净销售额获得分层销售提成。公司表示，本次收款已按协议约定完成，将计入公司财务报表。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651418741","title":"联邦制药(03933)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651418741","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651418741?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，于2026年7月15日，联邦生物科技已收取诺和诺德支付的UBT251注射液超重或肥胖适应症全球I期临床里程碑付款1350万美元(扣除丹麦预缴税后)。根据独家许可协议并受其条款和条件约束，联邦生物科技有资格收取最高18亿美元的潜在里程碑付款，视乎达成若干开发和销售里程碑而定，以及可收取基于该地区的年度净销售额计算的分层销售提成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651187494","title":"联邦制药(03933.HK)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651187494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651187494?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170510815","title":"联邦制药获诺和诺德支付1350万美元里程碑款项，用于II期UBT251试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1170510815","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170510815?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:03","pubTimestamp":1784174602,"startTime":"0","endTime":"0","summary":"7月15日，联邦制药宣布，已收到诺和诺德公司就II期UBT251试验支付的一笔1350万美元里程碑款项。此次付款标志着双方在相关药物开发合作中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160265604","title":"联邦制药（03933）多剂量玻璃酸钠滴眼液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1160265604","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160265604?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:36","pubTimestamp":1784028961,"startTime":"0","endTime":"0","summary":"2026年7月14日，联邦制药国际控股有限公司宣布，其全资附属公司珠海联邦制药股份有限公司中山分公司申报的玻璃酸钠滴眼液新规格——0.3%已获中国国家药品监督管理局药品注册批准，药品批准文号为“国药准字 H20269162”。联邦制药现有已上市规格为0.3%的单剂量产品，此次获批新增0.3%多剂量规格。联邦制药亦计划持续推进新产品研发，以提升在医药行业的竞争力和创新能力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170597","title":"联邦制药(03933.HK)：玻璃酸钠滴眼液新规格获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170597?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:17","pubTimestamp":1784027869,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116862052","title":"联邦制药旗下他达拉非片（5mg、10mg、20mg）获准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1116862052","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116862052?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:47","pubTimestamp":1783414020,"startTime":"0","endTime":"0","summary":"7月2日（路透社）——联邦制药（United Laboratories International Holdings Ltd，03933.HK）宣布，其生产的他达拉非片（规格为5毫克、10毫克和20毫克）已获得中国国家药品监督管理局的上市批准。\n这一批准标志着该产品正式获准在中国市场进行销售。他达拉非是一种用于治疗勃起功能障碍的处方药物，此次获批的三种剂量规格将为医生和患者提供更灵活的治疗选择。\n公司表示，此次获批将有助于进一步丰富其产品管线，并有望在未来为其业绩带来积极贡献。市场分析人士指出，该产品在中国市场的上市，可能会对相关领域的竞争格局产生一定影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180879229","title":"联邦制药五次回购合计275万股，涉资约2262.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180879229","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180879229?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:06","pubTimestamp":1783332404,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年7月6日发布翌日披露报表，公告6月16日至23日期间多次回购公司股份，并于当日悉数注销。根据公告信息，此次合计共回购2,750,000股普通股。上述回购股份数量约占该公司回购前已发行股份总数的0.14%，每股回购价介乎8.0742港元至8.3664港元，成交量加权平均价格约8.23港元，总涉资约2262.66万港元。公司表示，本次股份回购事宜已获得董事会正式授权，并遵守了香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药五次回购合计275万股，涉资约2262.66万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649462875","title":"联邦制药(03933.HK)7月6日注销合计85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649462875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649462875?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:04","pubTimestamp":1783332282,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174819528","title":"联邦制药更新6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1174819528","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174819528?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:21","pubTimestamp":1783326103,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司（03933）于2026年7月6日披露了截至2026年6月30日的股份变动月报表。报告期内，公司注册股本维持在3,800,000,000股，面值每股0.01港元，法定/注册股本总额38,000,000港元，均与上期一致。\n根据公告披露，截至6月底，已发行股份数量仍为1,973,026,508股，期间无新增发行、购回或注销股份。公司同时确认，当月无股份期权、可换股票据或其他股本类衍生工具的变动。\n截至报告期末，股本结构保持稳定，公司表示遵守香港联交所《上市规则》及相关法律规定。公告由公司秘书梁永康签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177670426","title":"联邦制药旗下他达拉非片（5mg、10mg、20mg）获中国上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1177670426","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177670426?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:36","pubTimestamp":1782985019,"startTime":"0","endTime":"0","summary":"联邦制药国际宣布，其生产的他达拉非片（规格为5毫克、10毫克及20毫克）已正式获得中国国家药品监督管理局的上市批准。\n此次获批标志着该药物可在国内市场进行商业化销售，为公司产品管线增添了重要一员。他达拉非是一种用于治疗勃起功能障碍的处方药物，此次获批的三种剂量规格将能满足不同患者的临床需求。\n药品上市许可的取得，预计将有助于拓宽联邦制药的收入来源，并巩固其在相关治疗领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648109505","title":"联邦制药(03933)：他达拉非片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2648109505","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648109505?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:36","pubTimestamp":1782984991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，公司全资附属公司珠海联邦制药股份有限公司中山分公司申报的他达拉非片通过中国国家药品监督管理局药品上市注册审批，批准文号分别为：国药准字 H20265009，国药准字 H20265010 及国药准字 H20265011。他达拉非片是一种 5 型磷酸二酯酶选择性抑制剂，用于治疗勃起功能障碍及勃起功能障碍合并良性前列腺增生。本次获批进一步丰富了公司的产品多元化布局，有助提升于男性健康领域的市场竞争力及品牌影响力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153395025","title":"联邦制药执行董事方玉平先生将于2026年6月30日卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1153395025","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153395025?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:56","pubTimestamp":1782813408,"startTime":"0","endTime":"0","summary":"联邦制药国际有限公司宣布，公司执行董事方玉平先生将于2026年6月30日正式退休离任。\n方玉平先生在任期间，为公司的战略发展及运营管理作出了重要贡献。董事会对其长期以来的服务与付出表示衷心感谢，并祝愿他退休生活愉快。\n此次人事变动自2026年6月30日起生效。公司表示，其现有管理团队结构稳固，本次变动不会对公司的日常运营及业务发展产生重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534378","title":"联邦制药(03933)：执行董事方煜平退休离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534378","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647534378?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:54","pubTimestamp":1782813269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，方煜平先生已从本公司执行董事的职务退休，自2026年6月30日生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647584391","title":"联邦制药(03933)将于7月22日派发末期股息每股0.26元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647584391","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647584391?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:22","pubTimestamp":1782793323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，该公司将于2026年7月22日派发末期股息每股0.26元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK1191","IE00B3M56506.USD","03933","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128554536","title":"联邦制药宣派末期股息每股0.26元，7月22日派息","url":"https://stock-news.laohu8.com/highlight/detail?id=1128554536","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128554536?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:12","pubTimestamp":1782792725,"startTime":"0","endTime":"0","summary":"联邦制药(03933)发布更新公告，明确截至2025年12月31日止年度的末期股息相关派息安排。公司宣派普通末期股息每股0.26元人民币，将以港元派付，每股换算为0.299034港元，汇率基准为1元人民币兑1.150131港元。\n股权登记日定于2026年7月10日，为符合获取股息资格，投资者须于7月8日下午4时30分前递交股份过户文件。除净日为7月7日，公司股份过户登记将自7月9日至7月10日暂停办理。股息派发日为2026年7月22日。\n本次股息不涉及代扣所得税。该派息方案已于2026年6月23日获得股东批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药宣派末期股息每股0.26元，7月22日派息","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100867433","title":"联邦制药宣派末期股息每股人民币26分，7月22日派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1100867433","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100867433?lang=zh_cn&edition=full","pubTime":"2026-06-29 23:02","pubTimestamp":1782745342,"startTime":"0","endTime":"0","summary":"联邦制药(03933)公告，截至2025年12月31日止年度的末期股息每股人民币26分的建议，已于股东周年大会上获得批准。该股息将以港元派付，按1.00港元兑人民币0.869466元的汇率折算，每股派发0.299034港元。预期末期股息将于2026年7月22日派发予2026年7月10日名列公司股东名册的股东。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"联邦制药宣派末期股息每股人民币26分，7月22日派发","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157434705","title":"联邦制药：6月23日回购50万股，耗资约411.41万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157434705","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157434705?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:46","pubTimestamp":1782226001,"startTime":"0","endTime":"0","summary":"联邦制药(03933)于2026年6月23日发布公告，披露在香港联交所场内进行股份购回的相关信息。\n本次回购股份数量为500,000股，占当日已发行股本约0.025342%。回购价格区间介乎每股港币8.13元至8.32元，合计支付约港币4,114,050元，折合约411.41万港元。\n回购完成后，公司已发行股本总数仍为1,973,026,508股，库藏股份数目维持为0股。公告同时显示，公司于2026年6月23日通过购回授权，可回购股份总数为197,302,650股，本次回购在授权范围内进行。\n公司确认已遵守香港联交所证券上市规则及相关法律法规。公告由公司秘书梁永康签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药：6月23日回购50万股，耗资约411.41万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":0.0917},{"period":"3month","weight":-0.0189},{"period":"6month","weight":-0.2267},{"period":"1year","weight":-0.3701},{"period":"ytd","weight":-0.2061}],"compareEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":0.1313},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.0549},{"period":"1year","weight":0.0449},{"period":"ytd","weight":0.0099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司，主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033072},{"month":2,"riseRate":0.736842,"avgChangeRate":0.075941},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024557},{"month":4,"riseRate":0.578947,"avgChangeRate":0.075619},{"month":5,"riseRate":0.631579,"avgChangeRate":0.035298},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.013942},{"month":7,"riseRate":0.55,"avgChangeRate":0.015909},{"month":8,"riseRate":0.473684,"avgChangeRate":0.025451},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006976},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000878},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023224},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011203}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}